Document is current

Article History

Received: 29 January 2026

Accepted: 3 September 2026

First Online: 10 September 2026

Declarations

Ethics approval and consent to participate: All protocols received ethical approval by the local Ethics Committee at TU Dresden under the reference number EK 14012011. All participants (or if underage, their guardians) gave written informed consent.

Competing interests: TK, CFR, MO, LCS, JAK, and SLD have nothing to declare. FIT and SE have received research grants from the “Marga and Walter Boll-Stiftung” and the B. Braun Stiftung. FIT has received funding from the Medical Faculty of the Technische Universität Dresden (“Habilitation Funding for Women”). VR has received payment for consulting and writing activities from Lilly, Novartis and Shire Pharmaceuticals, lecture honoraria from Lilly, Novartis, Shire Pharmaceuticals, and Medice Pharma, and support for research from Shire and Novartis. He has carried out clinical trials in cooperation with the Novartis, Shire and Otsuka companies. CMP has received consultancy or speaker fees from VärdePartners, Compass Pathways, and UCB. NP reports consulting fees from Bayer Vital GmbH, support from attending meetings and/or travel from Lilly and Novo Nordisk, speaker honoraria from Novo Nordisk, Lilly, APOGEPHA, GWT-TUD, Transmedac Innovations AG, Elbe-Gesundsheizszentrum GmbH, DACH, Intercom, honorarium as Guest Editor of Open Exploration and as Associate Editor of Elsevier outside the submitted work.